| Description | Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors. |
| In vivo | Rosmantuzumab（25 mg/kg；腹腔注射；每周一次；共4周）显著保护动物免受肝纤维化的发展[1]。另外，Rosmantuzumab（25 mg/kg；腹腔注射；每两周一次；共6周）在漂白霉素诱导的肺纤维化小鼠模型中显著抑制皮肤厚度、胶原沉积以及α-SMA阳性细胞的数量[1]。 |
| Synonyms | OMP-131R10 |
| molecular weight | N/A |
| CAS | 1684393-04-1 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. |